Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial
Mandar Paradkar, Bella Devaleenal D, Tisungane Mvalo, Ana Arenivas, Kiran T. Thakur, Lisa Wolf, Smita Nimkar, Sadaf Inamdar, Prathiksha Giridharan, Elilarasi Selladurai, Aarti Kinikar, Chhaya Valvi, Saltanat Khwaja, Daphne Gadama, Sarath Balaji, Krishna Yadav Kattagoni, Mythily Venkatesan, Radojka M. Savić, Soumya Swaminathan, Amita Gupta, Nikhil Gupte, Vidya Mave, Kelly E. Dooley, TuBerculous Meningitis in Kids (TBM-KIDS) Study Team, Shivali Agiwal, Rupali Ahire, Usha Balasubramanian, Manjushree Bendre, Jyoti Chandane, Kavita Chopade, Shamala Dalimbkar, Prasad Deshpande, Rajendra Dhage, Mahesh Ithape, Varsha Jadhav, Sonali Kante, Pallavi Kapre, Nawshaba Khan, Vandana Kulkarni, Renu Madewar, Shashibhushan Meshram, Kunal Muttha, Vaishali Nadgeri, Arti Nagargoje, Amita Nagraj, Aparna Nijampurkar, Prerana Onawale, Namrata Pawar, Prashant M. Pawar, Neeta Pradhan, Varsha Shaikh, Zaheda Shaikh, Dhananjay Shere, Gouri Wani, Rajesh Kulkarni, Uday Rajput, Mangalambal Ganesan, Gunasundari Arasan, Shakila Shankar, S Stella Mary, Sureshwari Karuppaiah, Leema Pauline, Snegha Karunakaran Pramila, Priyadharshini Arul, Sankar Ganesh, Luke Elizabeth Hanna, K Ramesh, M Kannan, Ruthra Vijayakumar, Surekha S Sivakumar, K Devika, Arun Natesh Radhakrishnan, Anis Preethi, S Rajkumar, N Saravanan, Geetha Ramachandran, A. K. Hemanth Kumar, M Dharman, V Sudha, Syed Hissar, Valarmathi Nagarajan, Linda Jennifer, R Supriya, R Manimegalai, Santhanam Kandan, Archana Maniselvi, Oli Puspha, S Vaishnavi, R Selvi, Logeswari Neelakandan, Mary Chiunda, Moreen Chunga, Madalo Kamanga, Portia Kamthunzi, Elizabeth Kanthiti, Abineli Mbewe, Emmie Msiska, Noel Mumba, Ian Zifa Phiri, Victor Palichina
Abstract
BACKGROUND: Pediatric tuberculous meningitis (TBM) commonly causes death or disability. In adults, high-dose rifampicin may reduce mortality. The role of fluoroquinolones remains unclear. There have been no antimicrobial treatment trials for pediatric TBM. METHODS: TBM-KIDS was a phase 2 open-label randomized trial among children with TBM in India and Malawi. Participants received isoniazid and pyrazinamide plus: (i) high-dose rifampicin (30 mg/kg) and ethambutol (R30HZE, arm 1); (ii) high-dose rifampicin and levofloxacin (R30HZL, arm 2); or (iii) standard-dose rifampicin and ethambutol (R15HZE, arm 3) for 8 weeks, followed by 10 months of standard treatment. Functional and neurocognitive outcomes were measured longitudinally using Modified Rankin Scale (MRS) and Mullen Scales of Early Learning (MSEL). RESULTS: Of 2487 children prescreened, 79 were screened and 37 enrolled. Median age was 72 months; 49%, 43%, and 8% had stage I, II, and III disease, respectively. Grade 3 or higher adverse events occurred in 58%, 55%, and 36% of children in arms 1, 2, and 3, with 1 death (arm 1) and 6 early treatment discontinuations (4 in arm 1, 1 each in arms 2 and 3). By week 8, all children recovered to MRS score of 0 or 1. Average MSEL scores were significantly better in arm 1 than arm 3 in fine motor, receptive language, and expressive language domains (P < .01). CONCLUSIONS: In a pediatric TBM trial, functional outcomes were excellent overall. The trend toward higher frequency of adverse events but better neurocognitive outcomes in children receiving high-dose rifampicin requires confirmation in a larger trial. CLINICAL TRIALS REGISTRATION: NCT02958709.